I-Corps: Mass spectrometry signal processing

这个I-Corps项目的更广泛的影响/商业潜力需要提高质谱商业用户的能力，通过使用更好的分子鉴定和定量技术，将更好的产品推向市场。质谱法的商业用户包括制药公司、生物技术公司和其他对公众健康和福祉有直接影响的公司，这些公司目前的社会影响和收入有限，部分原因是无法准确识别和量化质谱样品中的分子。 该技术的具体应用包括各种产品的研究和开发，包括诊断测试，新药和个性化医疗。该I-Corps项目将研究质谱数据处理服务的商业交付。基础技术通过结合先进的统计方法、质谱信号中存在但未被当前方法使用的附加信息以及用于解释的新方法来提高当前能力，以比当前质谱方法识别更多的分子，并且比当前方法具有更高的定量准确性。该研究特别能够检测低丰度分子，这些分子用目前的方法非常难以检测，并且比高丰度分子更有可能具有生物学意义。企业质谱用户可以使用低丰度分子的准确识别和定量来缩短上市时间，降低开发成本，并提高生产吞吐量和广泛的制药和生物技术产品创新的重要性。

The broader impact/commercial potential of this I-Corps project entails increasing the ability of commercial users of mass spectrometry to bring better products to market through the use of technology that better molecular identification and quantification. Commercial users of mass spectrometry include pharmaceutical companies, biotechnology firms, and other companies that have a direct impact on public health and wellbeing and are currently limited in social impact and revenue, in part, due to the inability to accurately identify and quantify molecules in mass spectrometry samples. Specific applications for the technology includes research and development on a variety of products, including diagnostic tests, novel drugs, and personalized medicine.This I-Corps project will investigate the commercial delivery of mass spectrometry data processing services. The underlying technology advances current capabilities by combining advanced statistical methods, additional information present in mass spectrometry signals but not used by current approaches, and novel methods for interpretation to identify more molecules than current mass spectrometry approaches with more quantitative accuracy than current approaches. The research is particularly capable of detecting low abundance molecules, which are exceptionally difficult to detect with current methods, and are more likely to have biological significance than high abundance molecules. Corporate mass spectrometry users can use accurate identifications and quantifications of low abundance molecules to shorten time-to-market, reduce development costs, and increase the production throughput and significance of innovations across a broad spectrum of pharmaceutical and biotechnology products.